source
- Encoded Therapeutics raises $275 million in Series F round for Dravet syndrome programEncoded Therapeutics announced closing a Series F financing round that brought in $275 million. The round was led by GV with participation from an undisclosed healthcare investor. The new capital…
- Kura Oncology launches Caspian Therapeutics to develop menin-inhibitor diabetes drug with $50M fundingKura Oncology has spun out a new biotech called Caspian Therapeutics to focus on menin inhibitors for diabetes and other cardiometabolic diseases. The company’s lead candidate, code-named KO-7246,…